The article, published on Monday, focused on the company Accelerated Evolution Biotechnologies Ltd. (AEBi).
"We believe that we will offer a complete cancer treatment in a year," says Dan Aridor, chairman of the Board of the company, as noted in the article.
The report indicates the treatment of the company called "MuTaTo (multi-purpose toxin) is basically at the scale of an antibiotic for cancer, a technology of the highest order interruption."
Despite the report, doctors who spoke with ABC11 in North Carolina expressed skepticism about claims.
"Although something new can always be found, it is very unlikely that a company has developed something that wants to cure all cancers within a year, that is, it is not plausible," said Dr. Benjamin Neel, the director of Laura and the Cancer Center Isaac Perlmutter at the NYU Langone Health.
Outside the camera, a spokesman for Duke Health refused to comment on the report, citing the lack of peer review, calling it "no story".
"I really think it's really unfair and almost cruel around these probably false hopes for cancer patients," said Dr. Neel.
The Jerusalem Post article reports that the company has tried with mice and is up-to-date with clinical trials.
"As far as I know, this product has not been in patients. History is full of claims based on studies based on tubes or animals that did not have absolutely no transferability to human disease," explained Dr. Neel.
In a statement to our sister station ABC11, Aridor said that AEBi is not a university research publication for peer review. Aventor noted that the company gave detailed lectures about its progress and its findings in three Drug Discovery conferences in 2017 and 2018 (two in Germany, one in Boston), and added that it received "wonderful reviews."
"When they present it for the peer review and it is published in a reputable newspaper and we can see it, this will be another story," said Neel.
AEBi received an American patent on its platform last month.
"Our cancer treatment will be effective from the first day, it will last for a few weeks and will not have minimal side effects at a much lower cost than the rest of the other treatments on the market," said Aridor.
Aries list in the article The Jerusalem Post as "our solution will be generic and personal."
The National Cancer Institute estimated that more than 1.7 million people would be diagnosed with cancer in 2018 and more than 600,000 would die from the disease this year.
Follow us on YouTube
Send news to the news board
More information on 6abc applications
(Copyright © 2019 WPVI-TV. All rights reserved.)